If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
We are pleased to announce that the accepted NOVELTY abstract on the humanistic burden of mild asthma was presented as an ePoster at the virtual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Conference, 16–19 November 2020. At NOVELTY baseline, many patients with physician-assessed mild asthma reported poor asthma symptom control or impairment of their disease-specific health status, with a subset of patients reporting poor overall current health status. The related abstract has been published in a supplement to the online version of Value in Health journal.1 Read more. The ePoster was titled, ‘The humanistic burden of mild asthma: evidence from the NOVELTY study’.
You are now leaving: http://aznoveltyproject.com/
By following this link you will be leaving the NOVELTY study website.
Please note that AstraZeneca does not take responsibility for the content displayed on other websites.